Roche Sees Early ROI on $2.7B Carmot Buy with Phase I Data for Obesity Candidate

Roche Tower_iStock, olli0815

Pictured: Roche tower in Basel, Switzerland/iStock, olli0815

Roche subsidiary Genentech on Thursday unveiled Phase Ib data for its investigational weight-loss treatment CT-388, demonstrating that a once-weekly subcutaneous shot could significantly lower body weight in healthy adults with obesity.

At 24 weeks of follow-up, CT-388 lowered body weight by 18.8% versus placebo. The effect was statistically significant, with a p-value less than 0.001, according to Genentech’s announcement. In addition, 100% of treated patients showed more than 5% weight loss at 24 weeks, while 45% of participants lost more than 20% of their body weight.

A subgroup analysis also showed that all pre-diabetic participants at the start of the study achieved normal blood glucose levels after 24 weeks of treatment, while those in the placebo group saw no meaningful change in glycemic status.

In terms of safety, CT-388 was well-tolerated in the Phase…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks